نتائج البحث - Nick Verber

  • يعرض 1 - 4 نتائج من 4
تنقيح النتائج
  1. 1
    Biomarkers in Motor Neuron Disease: A State of the Art Review

    Biomarkers in Motor Neuron Disease: A State of the Art Review حسب Nick Verber, Stephanie Shepheard, Matilde Sassani, Harry E. McDonough, Sophie A. Moore, James J. P. Alix, Iain D. Wilkinson, Thomas M. Jenkins, Pamela J. Shaw

    منشور في 2019
    احصل على النص الكامل احصل على النص الكامل
    Revisão
    أضف إلى المفضلة
    محفوظ في:
  2. 2
    Value of systematic genetic screening of patients with amyotrophic lateral sclerosis

    Value of systematic genetic screening of patients with amyotrophic lateral sclerosis حسب Stephanie Shepheard, Matthew Parker, Johnathan Cooper‐Knock, Nick Verber, Lee Tuddenham, Paul R. Heath, Nick Beauchamp, Elsie Place, Elizabeth Sollars, Martin R. Turner, Andrea Malaspina, Pietro Fratta, Channa Hewamadduma, Thomas M. Jenkins, Christopher McDermott, Dennis Wang, Janine Kirby, Pamela J. Shaw

    منشور في 2021
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  3. 3
    Multicentre appraisal of amyotrophic lateral sclerosis biofluid biomarkers shows primacy of blood neurofilament light chain

    Multicentre appraisal of amyotrophic lateral sclerosis biofluid biomarkers shows primacy of blood neurofilament light chain حسب Alexander G. Thompson, Elizabeth Gray, Nick Verber, Yoana Bobeva, Vittoria Lombardi, Stephanie Shepheard, Özlem Yildiz, Emily Feneberg, Lucy Farrimond, Thanuja Dharmadasa, Pamela Gray, Evan Edmond, Jakub Scaber, Delia Gagliardi, Janine Kirby, Thomas M. Jenkins, Pietro Fratta, Christopher McDermott, Sanjay Manohar, Kevin Talbot, Andrea Malaspina, Pamela J. Shaw, Martin R. Turner

    منشور في 2022
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  4. 4
    Efficacy and safety of low-dose IL-2 as an add-on therapy to riluzole (MIROCALS): a phase 2b, double-blind, randomised, placebo-controlled trial

    Efficacy and safety of low-dose IL-2 as an add-on therapy to riluzole (MIROCALS): a phase 2b, double-blind, randomised, placebo-controlled trial حسب Gilbert Bensimon, P. Nigel Leigh, Timothy Tree, Andrea Malaspina, Christine Payan, Hang‐Phuong Pham, Pamela Klaassen, Pamela J. Shaw, Ahmad Al Khleifat, Maria del Mar Amador, Shahram Attarian, Simon Bell, S. Beltran, Emilien Bernard, William Camu, Philippe Corcia, Jean-Christophe Corvol, Philippe Couratier, Véronique Danel, Rabab Debs, Claude Desnuelle, Aikaterini Dimitriou, John Ealing, Florence Esselin, Marie‐Céline Fleury, George Gorrie, Aude-Marie Grapperon, Adèle Hesters, Raúl Juntas‐Morales, Ivan Kolev, Géraldine Lautrette, Nadine Le Forestier, Christopher McDermott, Nicolas Pageot, François Salachas, Nikhil Sharma, Marie-Hélène Soriani, Jemeen Sreedharan, Juliette Svahn, Nick Verber, Annie Verschueren, Özlem Yildiz, Carey Suehs, Safaa Saker-Delye, C Müller, Christophe Masseguin, Hana Hajduchová, Janine Kirby, Cecília Garlanda, Massimo Locati, Henrik Zetterberg, Bernard Asselain, Ammar Al‐Chalabi

    منشور في 2025
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:

أدوات البحث: